Abstract
Schizophrenia is a major mental illness that is characterized by psychosis, apathy, social withdrawal and cognitive impairment. These abnormalities in patients results in impaired functioning in work, school, parenting, self-care, independent living, interpersonal relationships, and leisure. Although the search for the biological correlates of schizophrenia has met with limited success, new advances in genetics and pharmacology are promising. Here, we describe the symptoms, causes, diagnosis, strategies for treatment, and clinical impact of the currently available medications.
Keywords: Positive symptoms, negative symptoms, cognitive symptoms, brain circuits, dopamine, glutamate, genes, environmental factors, clinical criterias, imaging, typical antipsychotics, atypical antipsychotics.
Current Pharmaceutical Design
Title:Schizophrenia: Causes and Treatments
Volume: 19 Issue: 36
Author(s): Zafar U. Khan, Elisa Martin-Montañez and E. Chris Muly
Affiliation:
Keywords: Positive symptoms, negative symptoms, cognitive symptoms, brain circuits, dopamine, glutamate, genes, environmental factors, clinical criterias, imaging, typical antipsychotics, atypical antipsychotics.
Abstract: Schizophrenia is a major mental illness that is characterized by psychosis, apathy, social withdrawal and cognitive impairment. These abnormalities in patients results in impaired functioning in work, school, parenting, self-care, independent living, interpersonal relationships, and leisure. Although the search for the biological correlates of schizophrenia has met with limited success, new advances in genetics and pharmacology are promising. Here, we describe the symptoms, causes, diagnosis, strategies for treatment, and clinical impact of the currently available medications.
Export Options
About this article
Cite this article as:
Khan U. Zafar, Martin-Montañez Elisa and Muly Chris E., Schizophrenia: Causes and Treatments, Current Pharmaceutical Design 2013; 19 (36) . https://dx.doi.org/10.2174/1381612811319360006
DOI https://dx.doi.org/10.2174/1381612811319360006 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cyclo-Oxygenase (COX) Inhibiting Nitric Oxide Donating (CINODs) Drugs: A Review of Their Current Status
Current Topics in Medicinal Chemistry Regulation of Sulfotransferases by Xenobiotic Receptors
Current Drug Metabolism Climate Changes and Human Health: A Review of the Effect of Environmental Stressors on Cardiovascular Diseases Across Epidemiology and Biological Mechanisms
Current Pharmaceutical Design Monoamino Oxidase A: An Interesting Pharmacological Target for the Development of Multi-Target QSAR
Mini-Reviews in Medicinal Chemistry How Could We Reduce Antibiotic Use in Critically Ill Patients?
Infectious Disorders - Drug Targets β-Carboline Alkaloids: Biochemical and Pharmacological Functions
Current Medicinal Chemistry N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder
Current Psychiatry Reviews Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design A Review of the Nephrotoxicity of the Food Flavor Cinnamaldehyde
Current Bioactive Compounds The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Assessing Medication Problems in those ≥ 65 Using the STOPP and START Criteria
Current Aging Science Prostaglandin E2 Receptors as Potential Bone Anabolic Targets – Selective EP4 Receptor Agonists
Current Molecular Pharmacology Neuropsychiatric and General Interactions of Natural and Synthetic Cannabinoids with Drugs of Abuse and Medicines
CNS & Neurological Disorders - Drug Targets Muscarinic Receptors as Targets for Metronomic Therapy in Breast Cancer
Current Pharmaceutical Design Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy
Current Pharmaceutical Design Chemical and Clinical Development of Darinaparsin, a Novel Organic Arsenic Derivative
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetics of the Human MDR1 Multidrug Transporter
Current Pharmacogenomics Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Mas Receptor Agonists as Novel Antihypertensive Agents
Current Hypertension Reviews